| scholarly article | Q13442814 |
| P50 | author | Ingrid U. Scott | Q108861392 |
| Barbara A. Blodi | Q108861468 | ||
| Michael S Ip | Q108861512 | ||
| P2093 | author name string | Pravin U Dugel | |
| Paul C VanVeldhuisen | |||
| Neal L Oden | |||
| SCORE2 Investigator Group | |||
| Maria Figueroa | |||
| P2860 | cites work | Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report | Q73211634 |
| A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report | Q73211638 | ||
| Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group | Q73244978 | ||
| Computations for group sequential boundaries using the Lan-DeMets spending function method | Q73816032 | ||
| Modifying the design of ongoing trials without unblinding | Q74176293 | ||
| A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein | Q84558890 | ||
| The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia | Q24601205 | ||
| Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion | Q28192151 | ||
| Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study | Q28279362 | ||
| Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases | Q31076214 | ||
| Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors | Q32027429 | ||
| The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study | Q34162950 | ||
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema | Q35575496 | ||
| Hypertension: trends in prevalence, incidence, and control | Q36419526 | ||
| Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study | Q36825823 | ||
| Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion | Q37476656 | ||
| Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14 | Q38459932 | ||
| Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ). | Q39907057 | ||
| Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug | Q42322578 | ||
| Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators | Q42686675 | ||
| Results of bevacizumab as the primary treatment for retinal vein occlusions | Q42949067 | ||
| Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months | Q42975585 | ||
| Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. | Q43086468 | ||
| Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion | Q43274895 | ||
| Lamina puncture: pars plana optic disc surgery for central retinal vein occlusion | Q43948284 | ||
| Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation | Q44182411 | ||
| Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. | Q45919209 | ||
| Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results | Q46188845 | ||
| Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial | Q46202135 | ||
| Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons | Q46632464 | ||
| Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study | Q46796763 | ||
| Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial | Q46881066 | ||
| Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study | Q46969343 | ||
| Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases | Q46969353 | ||
| Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study | Q47753370 | ||
| The burden of adult hypertension in the United States 1999 to 2000: a rising tide. | Q50143429 | ||
| Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. | Q51496137 | ||
| VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. | Q54458722 | ||
| Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. | Q54521927 | ||
| Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group | Q71054248 | ||
| Baseline and early natural history report. The Central Vein Occlusion Study | Q72091370 | ||
| A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin | Q72761584 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 245-256 | |
| P577 | publication date | 2016-11-15 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | SCORE2 Report 2: Study Design and Baseline Characteristics | |
| P478 | volume | 124 |
| Q94468688 | A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study |
| Q38376975 | Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. |
| Q52687443 | Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. |
| Q88627052 | LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS |
| Q90629960 | Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial |
| Q46777540 | SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
Search more.